What is HC Wainwright’s Estimate for ABOS FY2024 Earnings?

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) – Research analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Acumen Pharmaceuticals in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst A. Fein now expects that the company will earn ($1.46) per share for the year, down from their prior estimate of ($1.01). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Acumen Pharmaceuticals’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Acumen Pharmaceuticals’ Q4 2024 earnings at ($0.37) EPS, FY2025 earnings at ($1.55) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at ($1.96) EPS and FY2028 earnings at ($1.82) EPS.

Other equities analysts also recently issued research reports about the company. Citigroup upgraded Acumen Pharmaceuticals to a “strong-buy” rating in a research note on Friday, July 26th. UBS Group dropped their price target on Acumen Pharmaceuticals from $14.00 to $6.00 and set a “buy” rating on the stock in a research report on Thursday, August 15th.

Acumen Pharmaceuticals Price Performance

ABOS opened at $2.39 on Monday. The firm has a market cap of $143.59 million, a P/E ratio of -1.73 and a beta of 0.04. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.43 and a current ratio of 10.43. Acumen Pharmaceuticals has a fifty-two week low of $2.08 and a fifty-two week high of $5.09. The firm has a 50-day moving average of $2.61 and a 200 day moving average of $2.77.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same period last year, the company posted ($0.24) earnings per share.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ABOS. Barclays PLC lifted its holdings in shares of Acumen Pharmaceuticals by 189.1% in the third quarter. Barclays PLC now owns 61,997 shares of the company’s stock worth $154,000 after buying an additional 40,551 shares in the last quarter. Geode Capital Management LLC lifted its stake in Acumen Pharmaceuticals by 6.5% in the 3rd quarter. Geode Capital Management LLC now owns 864,528 shares of the company’s stock worth $2,144,000 after purchasing an additional 52,395 shares in the last quarter. State Street Corp boosted its holdings in Acumen Pharmaceuticals by 18.3% in the 3rd quarter. State Street Corp now owns 516,406 shares of the company’s stock valued at $1,281,000 after purchasing an additional 79,841 shares during the period. FMR LLC increased its holdings in shares of Acumen Pharmaceuticals by 0.3% in the third quarter. FMR LLC now owns 2,028,117 shares of the company’s stock worth $5,030,000 after purchasing an additional 6,014 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Acumen Pharmaceuticals during the third quarter valued at $44,000. Institutional investors own 71.01% of the company’s stock.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.